Information on Voting Rights and Denominator

Liège, Belgium – January 31, 2025, 06.00 PM CET – Regulated information - In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings in issuers whose shares are admitted to trading on a regulated market, Hyloris Pharmaceuticals SA ('Hyloris') publishes the below information following a change in the remaining subscription rights.

- Total Share capital: EUR 140,001.87
- Total number of securities carrying voting rights: 28,000,374 (all ordinary shares)
- Total number of voting rights (= denominator): 28,000,374 (all relating to ordinary shares)
- Number of rights to subscribe to securities carrying voting rights not yet issued:
    - Pursuant to the ESOP Warrant plan 2020: 61,000 remaining subscription rights giving right to 61,000 ordinary shares*
    - Pursuant to the ESOP Warrant plan 2022: 24,813 remaining subscription rights giving right to 24,813 ordinary shares**
    - Pursuant to the ESOP Warrant plan 2025: 650,000 subscription rights giving right to 650,000 ordinary shares
    - In total: 735,813 subscription rights giving right to 735,813 ordinary shares**

*There is no change in the number of remaining subscription rights compared to the previous denominator press release of January 22, 2025, which included a decrease of 124,500 subscription rights of which 5,000 subscription rights were only formally confirmed after publication.

**Decrease of 4,000 subscription rights after publication of the previous denominator press release of January 22, 2025.

***

For more information, contact Hyloris:

Stijn Van Rompay, Co-CEO
Stijn.vanrompay@hyloris.com
+32 (0)4 346 02 07

Thomas Jacobsen, Co-CEO
Thomas.jacobsen@hyloris.com

About Hyloris Pharmaceuticals SA

Hyloris is a specialty biopharma company focused on innovating, reinventing, and optimizing existing medications to address important healthcare needs and deliver relevant improvements for patients, healthcare professionals and payors.

The Company's development strategy primarily focuses on leveraging existing regulatory pathways, such as the FDA's 505(b)2 pathway in the U.S or similar regulatory frameworks in other region which is specifically designed for pharmaceuticals for which safety and efficacy of the molecule have already been established. This type of regulatory pathway can reduce the clinical burden required to bring a product to market, significantly shorten the development timelines and reduce costs and risks.

Hyloris has built a broad, patented portfolio of 19 reformulated and repurposed value-added medicines that have the potential to offer significant advantages over available alternatives. Two products are currently in early phases of commercialization with partners: Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid post-operative pain treatment. Outside its core strategic focus, the Company also has 1 approved high barrier generic product launched in the U.S. and 2 high barrier generic products in development.

Hyloris is based in Liège, Belgium. For more information, visit www.hyloris.com and follow-us on LinkedIn.